Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06993792 · ClinicalTrials.gov registry record · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
A Phase 3 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
- 20
- Study locations
NCT06993792: Recruiting Phase 3 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
NCT06993792 is a Phase 3 study of Obesity and Type 2 Diabetes that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,200 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06993792, a Phase 3 study of Obesity and Type 2 Diabetes, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
Florida
- Accel Research Sites - DeLand Clinical Research Unit - DeLand
- Innovation Medical Research Center - Fort Lauderdale - Fort Lauderdale
- Indago Research & Health Center, Inc - Hialeah
- Encore Medical Research - Hollywood
- West Orange Endocrinology P.A. - Ocoee
- Care Access - Tampa - Tampa
- Conquest Research - Winter Park
Georgia
- Accel Research Sites - NeuroStudies Clinical Research Unit - Decatur
- Care Access - Decatur - Decatur
- Javara - Privia Medical Group Georgia - Savannah - Savannah
- North Georgia Clinical Research - Woodstock
California
- Norcal Endocrinology & Internal Medicine - San Ramon
- Southern California Clinical Research - Santa Ana
- Care Access - Thousand Oaks - Thousand Oaks
Arizona
- Clinical Research Institute of Arizona (CRI) - Sun City West - Sun City West
- Novak Clinical Research - Tucson - North La Cholla Boulevard - Tucson
Maryland
- Endocrine and Metabolic Consultants - Rockville
- Javara - Privia Medical Group - Silver Spring - Silver Spring
Idaho
- Solaris Clinical Research - Meridian
Louisiana
- Care Access - New Iberia - New Iberia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
What NCT06993792 shows while recruiting
NCT06993792 is an interventional study that assigns participants to a tested intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (47% higher).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06993792 names 20 study sites across 7 states, led by Florida, Georgia, California.
Frequently Asked Questions
What is clinical trial NCT06993792 about?
NCT06993792 is a clinical study titled "A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes". The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into eithe...
What is the current status of trial NCT06993792?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2025-05-15. Estimated completion is 2027-08.
What conditions does trial NCT06993792 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight.
What interventions are being tested in trial NCT06993792?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT06993792?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06993792 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06993792's enrollment target sits among peer trials
1,200 66th of 1053 higher than 987 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
-
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI